Sonoma Pharmaceuticals, Inc.
SNOA
$2.79
$0.8040.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.51% | 11.81% | -0.13% | -4.05% | -1.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.51% | 11.81% | -0.13% | -4.05% | -1.96% |
| Cost of Revenue | 14.80% | 1.24% | -5.18% | -4.82% | -7.75% |
| Gross Profit | 11.29% | 34.17% | 9.29% | -2.71% | 9.95% |
| SG&A Expenses | 5.28% | -9.06% | -13.81% | -14.28% | -28.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.07% | 1.58% | -1.90% | -2.26% | -12.01% |
| Operating Income | -0.54% | 21.24% | 6.42% | -2.93% | 31.50% |
| Income Before Tax | 26.86% | 38.59% | 19.87% | 2.93% | 27.26% |
| Income Tax Expenses | 128.57% | -200.00% | 43.33% | -512.50% | 85.36% |
| Earnings from Continuing Operations | 26.16% | 40.06% | 19.75% | 6.13% | 25.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.16% | 40.06% | 19.75% | 6.13% | 25.21% |
| EBIT | -0.54% | 21.24% | 6.42% | -2.93% | 31.50% |
| EBITDA | -1.05% | 21.94% | 7.25% | -1.87% | 32.65% |
| EPS Basic | 79.40% | 83.69% | 67.42% | 53.15% | 56.13% |
| Normalized Basic EPS | 79.23% | 83.01% | 68.62% | 53.44% | 57.34% |
| EPS Diluted | 79.40% | 83.69% | 67.42% | 53.15% | 56.20% |
| Normalized Diluted EPS | 79.23% | 83.01% | 68.62% | 53.44% | 57.34% |
| Average Basic Shares Outstanding | 225.63% | 266.14% | 214.33% | 167.71% | 103.81% |
| Average Diluted Shares Outstanding | 225.63% | 266.14% | 214.33% | 167.71% | 103.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
